Since MS patients urgently need new and more efficacious therapies to be used after disease outcome, we next investigated whether therapeutic treatment with the B1R antagonist DALBK (50 nmol/kg, i.p.)or the B2R antagonist HOE-140 (150 nmol/kg, i.p.)might be effective in controlling EAE. Here, BDKRB2 is linked to myeloid sarcoma.